Cantor Fitzgerald Reaffirms Its Overweight rating and $400 Price Target on Elevance Health, Inc. (ELV)

Elevance Health, Inc. (NYSE:ELV) is one of the 20 NYSE Stocks with the Lowest P/E Ratios.

As 2026 Marketplace rates were set, Cantor Fitzgerald reaffirmed its Overweight rating and $400 price target, drawing attention to Elevance Health, Inc. (NYSE:ELV) on September 16, 2025. According to the company, Elevance Health, Inc. (NYSE:ELV)’s weighted-average estimate is only around 40 basis points away from its proposed rates, and the majority of the first 15 states have authorized rates that are roughly in line with payor plans and considerably below the 30%+ increases that were initially expected.

Cantor pointed out that less than 25% of members have final rates and cautioned that outcomes may still be impacted by political unpredictability around the CMS Marketplace Integrity & Affordability Final Rule and the expiration of premium-enhanced subsidies at the end of 2025.

Elevance Health, Inc. (NYSE:ELV) also reiterated its 2025 earnings outlook, which calls for a benefit expense ratio of close to 90% and a projected $24.10 per diluted share, including net unfavorable items, and approximately $30.00 on an adjusted basis.

Health Benefits, CarelonRx, Carelon Services, and Corporate & Other are the four business segments that make up Elevance Health, Inc. (NYSE:ELV), a U.S.-based health benefits company. It is one of the Stocks with Low PE Ratio.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.